Citations 1
Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).
Kim, George P., Lenz, HeinzâJosef , Verma, Udit, Saltzman, Marc, Fuloria, Jyotsna, Khojasteh, Ali , Wiesenfeld, Martin, Cihon, Frank, Wagner, Andrea, Grothey, Axel, Cutsem, Eric Van , Wagner, Andrea
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e14649-e14649
